Eli Lilly and Co (LLY) : Home Federal Bank Of Tennessee scooped up 15 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 22,851 shares of Eli Lilly and Co which is valued at $1,905,773.Eli Lilly and Co makes up approximately 1.12% of Home Federal Bank Of Tennessee’s portfolio.
Other Hedge Funds, Including , Hl Financial Services boosted its stake in LLY in the latest quarter, The investment management firm added 149 additional shares and now holds a total of 51,421 shares of Eli Lilly and Co which is valued at $4,288,511. Eli Lilly and Co makes up approx 0.10% of Hl Financial Services’s portfolio.Strategic Advisors boosted its stake in LLY in the latest quarter, The investment management firm added 6,422 additional shares and now holds a total of 20,678 shares of Eli Lilly and Co which is valued at $1,660,030. Eli Lilly and Co makes up approx 0.93% of Strategic Advisors’s portfolio.Salem Capital Management Inc boosted its stake in LLY in the latest quarter, The investment management firm added 617 additional shares and now holds a total of 6,067 shares of Eli Lilly and Co which is valued at $481,477. Eli Lilly and Co makes up approx 0.27% of Salem Capital Management Inc’s portfolio.
Eli Lilly and Co closed down -0.04 points or -0.05% at $82.89 with 30,16,150 shares getting traded on Friday. Post opening the session at $83.07, the shares hit an intraday low of $82.64 and an intraday high of $83.45 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.
Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.